Precision BioSciences
Precision BioSciences develops ARCUS-based in vivo editing for gene elimination, excision, and insertion. Delivery and evidence differ by program; the company describes AAV delivery for its DMD gene-excision approach.
Corporate information
- Company entity
- Precision BioSciences
- Headquarters / principal office
- Durham, North Carolina, United States ↗
- Founded
- 2006 ↗
- Ownership / capital status
- Publicly tradedNasdaq-listed; DTIL ↗
- Official corporate reference
- https://precisionbiosciences.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Precision BioSciences develops ARCUS-based in vivo editing for gene elimination, excision, and insertion. Delivery and evidence differ by program; the company describes AAV delivery for its DMD gene-excision approach.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Precision BioSciences — official disclosure
- Precision BioSciences — official company page
- Precision BioSciences investor FAQs